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Abstract 
A recent genome-wide association study of Huntington’s disease (HD) implicated genes involved in DNA 
maintenance processes as modifiers of onset, including multiple genome-wide significant signals in a chr15 
region containing the DNA repair gene FAN1. Here, we have carried out detailed genetic, molecular and 
cellular investigation of the modifiers at this locus. We find that missense changes within or near the DNA 
binding domain (p.Arg507His and p.Arg377Trp) reduce FAN1's DNA binding activity and its capacity to rescue 
mitomycin C-induced cytotoxicity, accounting for two infrequent onset-hastening modifier signals. We also 
identified a third onset-hastening modifier signal whose mechanism of action remains uncertain but does not 
involve an amino acid change in FAN1. We present additional evidence that a frequent onset-delaying modifier 
signal does not alter FAN1 coding sequence but is associated with increased FAN1 mRNA expression in the 
cerebral cortex. Consistent with these findings and other cellular overexpression/suppression studies, knock-
out of FAN1 increased CAG repeat expansion in HD induced pluripotent stem cells. Together, these studies 
support the process of somatic CAG repeat expansion as a therapeutic target in HD, and clearly indicate that 
multiple genetic variations act by different means through FAN1 to influence HD onset in a manner that is 
largely additive, except in the rare circumstance that two onset-hastening alleles are present. Thus, an 
individual’s particular combination of FAN1 haplotypes may influence their suitability for HD clinical trials, 
particularly if the therapeutic agent aims to reduce CAG repeat instability.  
3 
Introduction 
Huntington's disease (HD; MIM 143100) is due to an expanded (>35) CAG trinucleotide repeat in HTT (MIM 
613004) 1 that encodes a lengthened polyglutamine segment in the large huntingtin protein. The HD mutation 
precipitates a constellation of neurological symptoms (e.g., involuntary movements, psychiatric disturbances, 
and cognitive decline)2 and leads to premature death.3 Both age-at-onset of characteristic motor signs and 
age-at-death show a strong inverse correlation with HTT CAG repeat length,4-7 but there is remaining variance 
that shows heritability, indicating that in addition to HTT, other genes play a role in determining the exact 
course of HD in any given individual. To identify genetic factors that modify HD age-at-onset, the GeM-HD 
Consortium carried out an initial genome-wide association study (GWAS) of ~4,000 HD subjects that revealed 
three genome-wide significant onset modification signals, including 2 opposing modifier signals at 15q13.2-
13.3.8; 9 Recently, an expanded GWAS of ~9,000 HD subjects showed that the timing of HD onset is due to a 
length-dependent property of the expanded CAG repeat rather than to polyglutamine size, and that the effects 
of this property are modified by at least 6 loci that harbor genes involved in DNA repair/maintenance 
processes.10 Together, these findings point to somatic CAG repeat expansion as the likely mechanism that 
determines age-at-onset, suggesting this process as a target for therapeutic intervention to delay or prevent 
HD onset. A detailed understanding of the modification effects could also underpin the use of genetic modifier 
genotype in clinical trial inclusion criteria and/or outcome analysis.  
Among other genes, the 15q13.2-13.3 modifier locus contains FAN1 (MIM 613534), which encodes a 
protein that participates in DNA interstrand cross-link (ICL) repair, and there is some support from model 
systems for reduced FAN1 levels resulting in trinucleotide repeat instability.11; 12 The recent GWAS produced 
evidence of additional onset modifier signals in this region and suggested that onset-hastening and onset-
delaying signals might be respectively associated with FAN1 missense variants that are potentially deleterious 
and with eQTLs that increased FAN1 mRNA levels in the cerebral cortex.10 To test these predictions and to 
better inform potential HD intervention strategies, we have explored this chromosome (chr) 15 locus and its 
modifier signals in greater detail, using molecular, cellular, and genetic strategies.  
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Material and Methods 
Subjects and phenotype 
HD subjects for our initial onset modifier GWA analysis (namely GeM-HD GWA123)9 and additional HD 
subjects for second GWA analysis (namely GeM-HD GWA12345) were described previously.10 Age-at-onset of 
motor symptoms was based mainly on rater's estimation; if such data were not available, we then used age-at-
onset data in the clinical records, or provided by family members or subjects. A stringent and robust 
phenotyping model for calculating individual deviation of age-at-onset from the expected age-at-onset based 
on one's expanded CAG repeat length was described previously.6 This residual age-at-onset, representing the 
age-at-onset that was not explained by the CAG repeat size, was the primary phenotype used for genetic 
analysis. HD subjects with positive and negative residual age-at-onset developed motor symptoms later or 
earlier than expected, respectively. For example, a HD participant with residual age-at-onset of 10 means that 
the subject developed motor symptoms 10 years later than expected based on one's expanded CAG repeat 
length. The distribution of residual age-at-onset of motor symptoms of study subjects was very similar to a 
theoretical normal distribution, allowing standard statistical analyses.10 Subject consents and the overall study 
design were reviewed and approved by the Partners HealthCare Institutional Review Board.10 
Genotype imputation and association analysis using the quantitative residual age-at-onset phenotype 
Subjects were genotyped in 5 HD modifier GWA studies as described previously.10 In order to obtain genotype 
data with the highest SNP density for the current study, we performed two independent genotype imputations 
using 1000 Genomes Project (KGP) data (phase 3, mixed population) and Haplotype Reference Consortium 
(HRC, European) as the reference panels using the Michigan Imputation Server. Each typed GWA data set 
was subjected to extensive quality control analyses implemented by the Michigan Imputation Server, with 
genotype imputation being carried out using EAGLE for the phasing and MINIMAC3 for the imputation. The 
two independent sets of imputed genotype data were then merged by supplementing HRC imputation data with 
KGP imputation-specific data. In the end, 9,058 samples10 were imputed for analysis in this study (4,414 males 
and 4,644 females). Since mixed effect models generated similar results to fixed effect models (data not 
shown), all SNPs (except 32 SNPs with imputation call rate < 100%) were analyzed to determine the level of 
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association between the minor allele count of a test SNP (additive model) and residual age-at-onset of subjects 
in a fixed effect model. Each fixed effect model for a given test SNP also included a set of covariates such as 
GWA study, sex, and the 4 top ancestry characteristics obtained from MDS (multi-dimensional scaling) 
analysis using genome-wide typed data by the PLINK program (version 1.07). After considering the patterns of 
association signals and recombination rate, our analysis focused on the chr15: 30900000-31500000 region. 
Low performing SNPs (5,206) were flagged (e.g., minor allele frequency < 0.01%, Hardy-Weinberg equilibrium 
p-value < 1E-6, or mean imputation R square values < 0.5). Minor allele frequency data were based on
imputed genotype data of the study subjects. Details of the original chr15 modifier haplotype-tagging SNPs are 
described elsewhere.10 Genomic coordinates were based on the GRCh37/hg19 assembly.  
CNV analysis 
Genotype intensity files were processed by the PENNCNV program to determine copy number variation (CNV) 
genotypes. We performed QC analysis by taking CNV segments that 1) were greater than 10 KB in size and 2) 
were determined by more than 10 sites. Frequencies of CNV (duplication and deletion) were calculated based 
on study subjects. Overall CNV frequencies are very low in the region; 124 subjects carry CNVs in the chr15 
region, so we performed association analysis using the residual age-at-onset phenotype excluding these 
subjects in order to judge the impact of CNVs on the observed SNP association signals. To test whether 
increased dosage of FAN1 affects age-at-onset, the residual age at onset of HD subjects carrying 3 copies of 
FAN1 were compared to that of HD subjects with two copies of FAN1. Statistical significance of increased 
FAN1 copy number was evaluated by an ANOVA model with the same covariates that were used in SNP 
association analysis.  
Nomenclature of modifier haplotypes 
To clarify each modifier haplotype on chr15, we used a naming system that was used previously.10 Briefly, the 
first number represents chromosome number, the letter 'M' stands for modifier, the next letter indicates the 
order of discovery (A represents first modifier locus in that chromosome), and the last number is given to 
distinguish apparent independent modifier effects at the locus. Although the 15AM4 haplotype was originally 
thought to represent a single independent modifier effect, further analysis here indicates that this haplotype 
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captures multiple separate modifier effects, leading us in this study to focus on 15AM1, 15AM2, 15AM3, and 
15AM5, each of which appears to capture a single independent modifier effect.  
Construction of nucleotide-resolution modifier haplotypes using KGP data 
We constructed full length modifier haplotypes based on haplotype-tagging SNPs and KGP data (phase 3). 
KGP chromosomes carrying the modifier haplotypes were identified based on refined modifier haplotype-
tagging SNPs (15AM1, 3; 15AM2, 46; 15AM3, 3; and 15AM5, 2; refer to Table S2). Then, the most frequent 
alleles at each site in the KGP chromosomes were taken as the consensus alleles of each modifier haplotype. 
Subsequent analysis was focused on modifier haplotype boundaries defined by the haplotype-tagging SNPs. 
Next, we split the variation sites in the reconstructed haplotypes into two groups depending on whether or not 
SNPs were tested in our association analysis. For SNPs that we tested and are also annotated in the KGP, we 
evaluated whether modification signals were contributed to by functional changes in proteins. Similarly, we 
examined annotations of SNPs that were not tested in our analysis but described in the KGP data set to judge 
a possibility of modification of HD due to functional changes in proteins.  
Functional annotation of SNPs  
SNPs were annotated based on the ExAC database to identify variations with functional impact; we focused on 
1) protein-altering variations and 2) deleterious mutations. Protein-altering variants included SNPs annotated
as frameshift variant, in-frame deletion, in-frame insertion, missense variant, protein altering variant, splice 
acceptor variant, splice donor variant, start lost, stop gained, or stop lost.  
Supplemental targeted capture sequencing analysis and genotype-based analysis 
In order 1) to confirm functional variations on the modifier haplotypes identified by KGP haplotype analysis, 2) 
to detect variations that were not annotated in KGP, and 3) to investigate their roles in modifying HD, we 
performed targeted capture sequencing analysis of selected representative HD samples carrying modifier 
haplotypes. Previously described haplotype-tagging SNPs were used to select samples for capture sequencing. 
Capture probes were designed to enrich the target region (chr15: 31050000-31314317) using the Agilent 
SureDesign online tool; tiling probes were designed to cover each base pair position by 5 independent probes. 
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This generated ultra-long 120-mer biotinylated complementary RNA baits, and these capture probes were 
used for solution-based SureSelect target enrichment.13 Briefly, genomic DNAs were sheared to produce 
smaller fragments, and libraries were prepared with sequence specific adaptors and indexes for multiplexing. 
DNA libraries were hybridized with biotinylated cRNA baits, which were complementary to regions to capture. 
The bait-library complexes were pulled down by magnetic beads. After the beads were washed, the RNA bait 
was digested to obtain the target DNA and subjected to sequencing using Illumina HiSeq 100bp paired-end 
sequencing at the Broad Institute. Samples were independently captured / indexed, and all capture materials 
were pooled together for sequencing in a single lane. Sequence reads were aligned (BWA and PICARD) for 
variant calling using the Genome Analysis Toolkit Best Practices workflow. At least 2.5 million sequence reads 
were produced for each sample, generating mean coverage of ~167X. Called variations were compared to 
KGP data. For shared variation sites between KGP data and our capture sequencing data, we evaluated the 
allele frequency of functional variations identified from KGP haplotype analysis to confirm the presence of 
functional variations with expected frequencies. For capture sequencing-specific variations, we focused on 
exon variations with expected allele frequency of the causal variation.  
eQTL analysis using the CommonMind Consortium data and co-localization analysis 
We obtained genotype and expression data from the CommonMind Consortium (CMC) in order to compare 
significances of SNPs in HD modifier association analysis with those in gene level eQTL analysis results. A 
standard eQTL analysis was performed by modeling expression levels of FAN1 as a function of a test SNP 
(additive model), MDS covariates, and sex in a fixed effect model. SNPs in 1MB flanking regions of FAN1 were 
tested (2,732 SNPs in 451 samples including 269 males). Then, SNPs were matched between HD GWA 
analysis and CMC eQTL analysis based on chromosome, genomic location (GRCh37/hg19), reference allele, 
and alternative allele. 1,840 SNPs were shared by HD GWA data and CMC eQTL data, and subsequently 
compared. Co-localization analysis was based on 'coloc' R package (version 3.2-1) in the R environment. 
Posterior probability of 1) causal variant for HD modifier trait only, 2) causal variant for CMC eQTL trait only, 
and 3) one common causal variant were calculated by 'coloc.abf' function using summary data for HD GWAS 
and CMC eQTL.  
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Cell culture 
HEK293T cells and FAN1 knock-out HEK293T cells were cultured in DMEM (Invitrogen) supplemented with 
10% fetal bovine serum (Hyclone) and Penicillin-Streptomycin (Invitrogen) at 37°C and 5% CO2. 
Lymphoblastoid cell lines (LCLs) derived from HD subjects were cultured in RPMI (Sigma-Aldrich) 
supplemented with 5% fetal bovine serum and Penicillin-Streptomycin at 37°C and 5% CO2.  
FAN1 knock-out HEK293T cells 
To obtain modifier FAN1 protein extracts without endogenous FAN1, we inactivated endogenous FAN1 in the 
HEK293T cells by the CRISPR/Cas9 approach. A FAN1-specific gRNA (target site, chr15:31206161-
31206180) was selected from the GeCKO library,14; 15 and potential off-target sites were checked in the 
Optimized CRISPR design website. Annealed oligos were inserted into the lentiCRISPR V2 vector (Addgene, 
52961) as recommended in the GeCKO website.14; 15 HEK293T cells were then transfected with FAN1-
targeting CRISPR/Cas9 plasmid using Lipofectamine 2000 (Invitrogen). After selection with 1 µg/ml of 
Puromycin (Invitrogen) for 48 hours, single cells were picked and independently expanded to establish clonal 
lines. Two lines were developed and further analyzed by Sanger sequencing. The levels of FAN1 protein were 
evaluated by immunoblot analysis (FAN1 antibody, Abcam, ab95171) using whole cell lysate (50 µg). The 
location of FAN1 protein band in the immunoblot analysis was confirmed by FAN1-overexpressed samples. 
Cloning of FAN1 modifier haplotypes and generation of full length cDNA expression vectors 
We selected a panel of HD LCLs to generate full-length FAN1 expression vectors; cells were selected based 
on the genotypes of haplotype-tagging SNPs (rs150393409 for 15AM1; rs35811129 for 15AM2). Total RNA 
samples were prepared by RNeasy Plus mini kit (Qiagen), and cDNA was subsequently prepared by 
SuperScript III first-strand kit (Invitrogen). The concentration and purity of DNA and RNA samples were 
determined using NanoDrop (ND-1000). We used cDNA to amplify full length 15AM1, and 15AM2 FAN1 
(primers, 5'-GGCGGCCGCAATGATGTCAGAAGGGAAACCTCCTGAC-3' and 5'-
CAGATCTTTAGCTAAGGCTTTGGCTCTTAGCTCCAAC-3'). Amplified DNA was isolated from the agarose gel 
and extracted for digestion by NotI and BglII. Digested DNA was inserted into a linearized FLAG-tagged 
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mammalian expression vector (pFLAG-CMV-4 expression vector; Sigma-Aldrich, E7158). The vector for 
15AM3 was generated by site directed mutagenesis using 15AM2 plasmid. For all plasmids, full sequence was 
verified by Sanger sequencing analysis. Our FAN1 plasmids confirmed the sequences reconstructed from KGP 
haplotype analysis and supplemental capture sequencing analysis. 
Qualitative detection of interaction between FAN1 and 3' flap DNA substrate 
To qualitatively assess whether FAN1 protein interacts with 3' flap DNA substrate, we performed EMSA 
(electrophoretic mobility shift assay)-type assays. Our 3' flap DNA substrate consisted of oligonucleotides that 
have been used previously in a crystal structure study, and shows strong binding affinity to FAN1.16 The 
constituents of this complex are: 1) a 40-nucleotide long oligo with biotin at the 5' end (5'-
CCCGTCCAGGTCTCGTCCGCGCCACTCGTGTCCAGCGTCG-3'; namely Biotin-A1), 2) a post-nick probe 
with 5'-phospho (5'-TGCGGACGAGACCTGGACGGG-3'; namely B2), and 3) a pre-nick oligo (5'-
CGACGCTGGACACGAGTGGCTTTTTTTT-3'; namely C3).16 These three oligos were annealed by incubating 
at 95°C for 5 min and gradually cooling to 4°C in annealing buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl, pH 
8.0).16 Annealing reaction included 5 femtomol of A1, 10 femtomole of B2, and 10 femtomole of C3 in 50 µl of 
annealing buffer.  Fig. S7A shows sequences and a conceptual illustration of the annealed oligos. To detect 
interaction between FAN1 and DNA substrate, nuclear extracts obtained from HEK293T cells or FAN1 knock-
out HEK293T cells (prepared by the NE-PER Nuclear and Cytoplasmic Extraction Reagent; Pierce, 78833) 
were incubated with annealed DNA oligos; 10 µg of nuclear extract were incubated with annealed DNA oligos 
in 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 ng/µl Poly (dI•dC), 5% glycerol, 0.1 mg/ml BSA, 10 mM CaCl2 and 
0.1 mM DTT at 4°C for 30 min. The binding mixtures were then resolved on 5% TBE gels (Bio-Rad), and 
FAN1-DNA substrate interaction was detected by Biotin-Streptavidin Detection Kit (Pierce, 20148). FAN1-DNA 
substrate interaction was also confirmed by excess amount (1000X) of non-labeled DNA oligo complex 
(competitor comprising non-biotinylated A1, B2, and C3). Due to the low performance of a commercially 
available FAN1 antibody, super shift assay was not performed.  
Quantitative evaluation of DNA binding activities of modifier FAN1 
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To determine the levels of DNA binding activity of specific modifier haplotype FAN1 protein, we performed 
quantitative pull-down assays. The same oligo annealing procedures were performed to generate 3' flap 
structure except for the amounts of oligos; we incubated 10 picomole of biotinylated A1 (Biotin-A1), 20 
picomole of B2, and 20 picomole of C3 in a 30 µl reaction volume. 10 µl of annealed oligos (i.e., 3' flap DNA 
substrate) was used for each reaction with nuclear lysate. To generate modifier FAN1 protein, FAN1 knock-out 
HEK293T cells were transfected with FAN1 expression vectors for 72 hours (Lipofectamine 2000), and nuclear 
extracts were prepared (NE-PER Nuclear and Cytoplasmic Extraction Reagent; Pierce, 78833). One hundred 
µg of individual nuclear extract was used for binding with DNA substrate in 300 µl of binding buffer (PBS, pH 
7.4, protease inhibitors; on ice). FAN1-DNA complex was then incubated with 30 µl of Dynabeads MyOne 
Streptavidin (Invitrogen) at room temperature for 90 min.17 After washing with PBS (3 times), the FAN1-DNA 
complex was dissociated with 0.1% SDS in NuPAGE LDS Sample Buffer (Invitogen), and resolved on 
NuPAGE gels (Thermo; 4-12% Bis-Tris Protein Gel). The amount of FAN1 pulled down by 3' flap DNA was 
determined by Immunoblot assay by anti-FAN1 antibody (Abcam ab95171). Densitometric quantification of 
bands was performed by Multi Gauge version 2.3 (Fujifilm). The quality of nuclear extracts was evaluated by 
Lamin A/C in the input (Cell Signaling, #4777; data not shown). FAN1 DNA binding activity data were 
normalized by the amount of FAN1 in the input. In addition, DNA binding activity of different modifier FAN1 was 
determined using annealed oligos hypothesized to form a DNA hairpin/loop structure. To generate CAG 
repeat-induced DNA hairpin/loop structures, we used CAG repeat oligos (5'-CGACGCTGGACACGAGTGGC-
[CAG]n-GCGGACGAGACCTGGACGGG-3'), where n= 0, 2, 4, 6, 8, or 10 CAGs inserted into the reverse 
complementary sequence of Biotin-A1.  Annealing these oligos to Biotin-A1 (using the same procedures as 
above) was used to generate a complex of Biotin-A1 and CAG repeat oligos with a CAG loop-outs with the 
potential to form hairpins. To check the annealed oligos, we incubated 5 femtomol of Biotin-A1 and 10 
femtomol of CAG repeat oligo in 50 µl of annealing buffer. The annealed oligos were resolved on 5% TBE gels 
and detected by Biotin-Streptavidin Detection Kit. For quantitative DNA binding assays, we annealed 10 
picomole of Biotin-A1 and 20 picomole of CAG repeat probe in a 36 µl reaction volume. Ten µl of annealed 
oligos was incubated with overexpressed FAN1 nuclear lysate (100 µg). Procedures for binding, streptavidin 
pull down, and data normalization were same as those in assays using 3' flap DNA substrate. Nuclease activity 
was not determined in these assays because these assay conditions were not optimal for measuring FAN1 
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catalytic activity, and the genetic investigation suggested a role for altered DNA binding or expression levels 
rather than FAN1 catalytic activity.12 
Effects of modifier FAN1 on cytotoxicity induced by mitomycin C (MMC) 
We determined whether our modifier FAN1 expression vectors could rescue MMC-mediated cytotoxicity in the 
absence of endogenous FAN1 in HEK293T cells. Briefly, FAN1 knock-out HEK293T cells were transfected 
with FAN1 overexpression vectors (Invitrogen, Lipofectamine 2000, 72 hours). Then, FAN1 knock-out 
HEK293T cells and FAN1-overexpressing knock-out HEK293T cells were treated with either DMSO or MMC 
(10 µM for 24 hours; Abcam). Cell viability of FAN1 deficient cells was determined by CellTiter-Glo luminescent 
cell viability assay (Promega). Each condition was tested in 5 wells, and the entire experiments were repeated 
4 times. We also determined whether HD LCLs with different modifier FAN1 haplotypes show different 
sensitivity to this DNA damaging agent. Ten different HD LCLs were used: 1) 5 lines carrying one copy of 
15AM1 FAN1 (HTT CAG: 37, 41, 41, 41, 53) and 2) 5 LCLs carrying at least one copy of 15AM2 (HTT CAG: 
41, 42, 49, 52, 53). HD LCLs were plated in 96-well plates at 2x104 cells/well and treated with MMC for 48 
hours. Cell viability was determined by CellTiter-Glo Luminescent Cell Viability Assay. For each concentration, 
6 wells were used, and 4 independent experiments were performed.  
FAN1 knock-out HD iPSC and CAG repeat expansion assay 
To examine the effect of FAN1 knock-out on CAG expansion, we used an iPSC line derived from a HD subject 
fibroblast (GM04723) with 72 and 15 CAG repeats and two copies of onset-delaying modifier haplotype 15AM2 
10 generated as described by the HD iPSC Consortium.18 Cells were maintained in mTeSR1 with 5X 
supplements (Stemcell technologies, 85850) at 37°C and 5% CO2. The size of normal CAG repeat is expected 
to be 15 in all cells but the length of expanded CAG repeat may differ from 72 in individual clones due to low 
level repeat mosaicism. To generate FAN1 knock-out in these iPSC, cells were treated 10 µM of ROCK 
inhibitor (Millipore, 688000) 1 hour before transfection with FAN1 specific gRNA containing pLentiCRISPR V2 
plasmid and empty vector by Amaxa Human Stem Cell Nucleofector Kit 1 (Lonza, VPH-5012). After selection 
with Puromycin (0.2 µg/ml for 48 hrs; Invitrogen), single cells were picked and independently maintained. From 
these, two knock-out iPSC clonal lines were generated and respectively confirmed by Sanger sequencing (1 
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nucleotide insertion and 8 nucleotide deletion in knock-out clonal line #1; 1 nucleotide insertion and 2 
nucleotide deletion in knock-out clonal line #2). The control and knock-out cells all showed similar growth rates 
(data not shown). Genomic DNAs from each iPSC clonal cell line were collected monthly for 6 months 
(DNeasy, Qiagen) for PCR amplification with HD CAG repeats specific primers.19 The distribution of CAG 
repeats in the bulk DNA was determined by a standardized fragment-based genotyping assay using an 
ABI3730XL sequencer, and the CAG expansion index was calculated from GeneMapper traces as previously 
described, with a threshold of 10% relative to the maximum height peak.19 
Immunoblot assay 
Cells were washed three times with PBS and incubated in cell lysis buffer (Cell Signaling, #9803) containing 
protease inhibitors (Roche, #11697498001). Protein lysate was separated on 4-12% Bis-Tris gel (Invitrogen) 
and transferred to PVDF membranes. After blocking in 5% milk in TBS containing 0.1% Tween-20, the 
membranes were incubated overnight at 4°C with primary antibodies. The following primary antibodies were 
used: anti-FAN1 (Abcam, ab95171), anti-FLAG (Sigma-Aldrich, F1804), and anti-actin (Sigma-Aldrich, A4700). 
After washing, the blots were probed with anti-mouse, or anti-rabbit IgG-HRP secondary antibodies and 
visualized by ECL (PerkinElmer). 
Programs and Statistics 
R (version 3.3.3) was used for plotting unless otherwise specified. R 3.5.3 was used for the co-localization 
analysis. For human FAN1 molecular and cell experiments, the values are expressed as the mean ± standard 
error of independent experiments. For group comparisons, Student's t-tests were performed.  
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Results 
Definition of modifier signals 
The most recent GWAS of ~9,000 HD subjects that implicated multiple significant modifier signals (two 
infrequent haplotypes: 15AM1, 15AM3 and two frequent haplotypes: 15AM2, 15AM4) included 1,963 QC-
passed SNPs, imputed in the chr15:30,900,000-31,500,000 region (GRCh37/hg19) using the Haplotype 
Research Consortium (HRC) as a reference panel.10 To achieve a more comprehensive high density definition 
of these modifier signals, we have augmented the analysis to now include 13,294 variants in this region by 
adding short genetic variations (SGV: including both SNPs and indels) imputed using the 1000 Genome 
Project (KGP) as reference panel (Fig. S1). Association analysis using residual age-at-onset of motor signs 
(i.e., age-at-onset corrected for individual CAG repeat size) as the phenotype revealed robust onset 
modification signals that crossed FAN1 and two additional protein coding genes (MTMR10 and part of TRPM1) 
(Fig. 1). Of the 13,294 imputed SGVs, 148 were protein-altering (i.e., frameshift, in-frame deletion, in-frame 
insertion, missense, splice acceptor, splice donor, start lost, stop gained, or stop lost) and some of these were 
predicted to be deleterious (Table S1). Two, rs150393409 and rs151322829, represent the FAN1 missense 
changes, p.Arg507His and p.Arg377Trp, reported to tag the 15AM1 and 15AM3 modification signals, 
respectively (Fig. 1, red triangles).  
To test the degree of independence of all modifier signals, we carried out association analyses in which 
we conditioned separately on each of the modifier-tagging SNPs defining 15AM1, 15AM2, 15AM3, and 15AM4 
(Fig. S2). The results indicated that significance of the tag SNPs for each of the first three signals was little 
affected by conditioning on each other, whereas significance of the 15AM4 tag SNP was respectively 
increased and decreased by conditioning on the 15AM1 and 15AM2 signals. Reciprocally, conditioning on the 
15AM4 tag SNP respectively increased and decreased the significance of 15AM1 and 15AM2 tag SNPs. Thus, 
the very frequent 15AM4 tag SNP does not in fact capture a single discrete modifier effect but rather a 
combination of modifier effects; consequently we excluded it from subsequent analyses to delineate individual 
modifier signals. Because both 15AM1 and 15AM3 signals are captured by infrequent alleles (respectively, 
~1.4% and ~0.7% frequency in the study population), we next removed the 381 subjects carrying either of 
these tag SNPs to simplify more detailed analyses (namely, drop-out analysis). We then repeated the 
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association analysis with this slightly reduced sample size (n=8,677) (Fig. 2A). After removal of the onset-
hastening signals, the association analysis no longer identified rs35811129 (Fig. 2A) as best capturing the 
onset-delaying 15AM2 signal, but rather pointed to the indel variant rs66632437 (p-value, 1.3E-25) and SNP 
rs8034856 (p-value, 1.4E-25) as better tags of this modifier effect. Since indels are not imputed with the HRC 
reference data, we chose rs8034856 (Fig. 2A) as the new tag SNP for analyses of 15AM2. Conditioning on this 
new 15AM2 tag SNP revealed a previously unrecognized genome-wide significant modifier signal (Fig. 2B), 
which we have termed 15AM5 (Fig. 2A, cyan). This third onset-hastening modifier effect is tagged by 
rs79213781, with a minor allele frequency (MAF) of ~1.9% (effect size, -2.55/year/minor allele). Conditional 
analysis of each of the 15AM1, new 15AM2, 15AM3 and 15AM5 tag SNPs confirmed 15AM5 to be separate 
from the previously defined modifier signals (Fig. S3). Repeating the association analysis after removal of 
samples carrying any of 15AM1, 15AM3, or 15AM5 tag SNPs and conditioning on the new 15AM2 peak SNP 
revealed only signals with p-values < 5E-04 (data, now shown), suggesting that any additional signals which 
emerge as significant with a further increase in GWAS sample size will represent low frequency alleles. Finally, 
conditioning on all independent modifier haplotypes (15AM1, 15AM2, 15AM3, and 15AM5) eliminated all signal 
detected by 15AM4 (Fig. S4).   
In addition to the SGV association results, Fig. 1 also shows the frequency of copy-number variation 
(CNV) across the region. CNVs were seen in only 124 of 9,058 HD subjects (a low overall frequency in the 
study population), and these did not align with the patterns of SGV association signals (Fig. 1). Exclusion of 
HD subjects with CNVs had a minimal impact on single SGV association analysis (Fig. S5A), indicating that 
CNV is not responsible for any of the individual 15AM1, 15AM2, 15AM3, or 15AM5 modifier signals. However, 
eight subjects who carried 3 complete copies of FAN1 showed delayed onset (p = 0.016) compared to those 
without CNV (Fig. S5B), supporting the possibility that in HD, increased FAN1 levels are protective.  
Construction of nucleotide-resolution modifier haplotypes and functional annotation 
For each individual modifier effect, we defined the extent of the chr15 region that contains the modifier-tagging 
SNP and those SGVs in strong linkage disequilibrium with it (r-square > 0.8) (Table S2). From the normal 
chromosomes of the KGP (phase 3), we then constructed nucleotide-resolution modifier haplotypes 
representing the consensus alleles of those KGP chromosomes that carry the tag SNPs and delineated 
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protein-altering SGVs. We examined separately those SGVs that were tested in our association analysis and 
those not-tested (Table 1). For example, in the KGP data, 2,836 SGVs are present within the boundaries of 
modifier haplotype 15AM1; 1,703 of these were imputed and tested in our SNP association analysis. Among 
these tested variants, only two SNPs are protein-altering: 1) rs150393409 (MAF, 1.44% in the study subjects; 
FAN1 p.Arg507His; annotated as deleterious and possibly damaging in SIFT and PolyPhen, respectively),20-22 
and 2) rs3784588 (MAF, 6.72% in the study subjects; TRPM1 p.Val1434Ile based on NM_001252020.1; 
tolerated/benign). While the former produced the most significant p-value in our association analysis (p-value, 
6.7E-29 in a fixed model), the latter showed non-genome-wide significance (p-value, 1.7E-07 in a fixed model). 
By contrast, the KGP data haplotype for the onset-delaying 15AM2 effect did not reveal any alternative alleles 
that change amino acid sequence at tested variation sites. The 15AM3 modifier haplotype has only one 
protein-altering variant, the 15AM3-tag SNP rs151322829 (MAF, 0.7% in the study subjects; FAN1 
p.Arg377Trp;  deleterious/damaging; p-value, 9.3E-9 in a fixed model). The 15AM5 modifier haplotype carries
a protein-altering variant only in MTMR10 (rs6493352; MAF, 17.4% in the study subjects;  p.Arg648His; 
tolerated/benign; p-value, 1.3E-04, in a fixed model). Of the SNPs listed in the KGP data that were not imputed 
and thus not tested in our association analysis, none has an alternative allele that is protein-altering on any of 
the modifier haplotypes.  
We also performed targeted DNA capture sequencing analysis 13 of 32 representative HD individuals 
bearing the 15AM1, 15AM2, 15AM3, and 15AM5 tag SNPs to discover functional variants that might have 
been missed in our imputed SGV association analysis and in the KGP data analysis (Table 1). Given the 
frequencies of the tag SNPs, we were able to analyze heterozygotes for 15AM1, 15AM3 and 15AM5 and 
homozygotes for 15AM2. Consequently, causal variants were expected to be observed at 50% frequency in 
the former and at 100% frequency in the latter. Consistent with the GWAS data and functional annotation of 
modifier haplotypes in KGP data, the capture sequencing confirmed the protein-altering SNPs at expected 
European ancestry allele frequencies for 15AM1 (rs150393409), 15AM3 (rs151322829), and 15AM5 
(rs6493352). Interestingly, one of the subjects homozygous for the onset-delaying 15AM2 modifier haplotype 
was found to harbor a very rare nonsense mutation (rs184745027; FAN1 pArg952Ter; MAF, 0.0071% based 
on gnomeAD v2.1.1) in one FAN1 allele. This subject had onset 11.7 years earlier than expected from their 
inherited CAG repeat length (CAG=41; observed age-at-onset=44 yrs; expected age-at-onset=55.7 yrs), 
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consistent with the heterozygous loss of FAN1 function producing an onset-hastening effect. Together, these 
detailed analysis of the chr15 HD modifier locus point to FAN1 as the only gene common to all 4 modifier 
haplotypes and the only gene with evidence for causal protein sequence alterations, suggesting in particular 
that the 15AM1 and 15AM3 modifier effects are due respectively to the FAN1 p.Arg507His and p.Arg377Trp 
missense variants (Table S3).  
Reduced DNA binding activity of 15AM1 and 15AM3 FAN1 proteins 
These postulated causal 15AM1 (p.Arg507His) and 15AM3 variants (p.Arg377Trp) involve amino acids in and 
near the DNA binding domain of FAN1 (Fig. 3A), respectively, raising the possibility that they affect FAN1 DNA 
binding activity. To test this hypothesis, we generated full-length expression constructs for 15AM1 and 15AM2 
FAN1 from HD lymphoblastoid cells (LCLs); we then derived a 15AM3 construct from the 15AM2 construct by 
site directed mutagenesis. Sanger sequencing confirmed that these full-length FAN1 expression constructs 
matched the KGP haplotype/sequence data, enabling us to test the effect of the selected variants on the DNA 
binding activity of FAN1. In qualitative in vitro assays using wild-type (WT) and FAN1-knock-out cells (Fig. S6), 
we confirmed that FAN1 interacts with 3' flap DNA substrate (Fig. S7).16 Quantitative in vitro assays (Fig. S8) 
showed that the DNA binding activities of FAN1 p.Arg507His (15AM1) and FAN1 p.Arg377Trp (15AM3) are 
significantly reduced compared to the 15AM2 FAN1, supporting the proposed functional impact of these 
missense variants (Fig. 3B). Reduced binding of FAN1 p.Arg507His (15AM1) and FAN1 p.Arg377Trp (15AM3) 
was also observed in binding assay using CAG loop-out, although not in a structure-specific fashion (Figs. S9-
S10; Fig. 3C).  
Functional consequences of reduced FAN1 DNA binding activity 
We next determined whether the reduced DNA binding activity of 15AM1 and 15AM3 FAN1 is reflected in a 
functional impact on cells. We first evaluated whether FAN1 rescued cytotoxicity caused in FAN1-deficient 
HEK293T by mitomycin C (MMC).23 15AM2 FAN1 significantly rescued cells from this toxicity (Fig. 4A) 
whereas FAN1 p.Arg507His (15AM1) and FAN1 p.Arg377Trp (15AM3) did not. In addition, HD LCLs carrying 
the 15AM1 modifier showed increased sensitivity to MMC-mediated toxicity and consequently reduced viability 
compared to those with the 15AM2 modifier (Fig. 4B; Fig. S11), demonstrating that this measure of DNA repair 
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function of FAN1 differs by haplotype and further implicating FAN1 variation as the source of the HD modifier 
effects.  
The suggestion that the onset-hastening and onset-delaying modifier effects both act through an 
altered rate of somatic expansion of the CAG repeat has recently received mixed support from introduction of 
an HTT exon 1 transgene into FAN1-deficient osteosarcoma cells and from FAN1 shRNA suppression in a 
human induced pluripotent stem (iPS) cell line with a long, inherently unstable CAG repeat (~121 CAGs from a 
subject with 109 CAGs).12 To confirm that the capacity of FAN1 to influence HD onset is reflected in its ability 
to suppress somatic HTT CAG expansion at the endogenous HTT locus in a subject whose CAG repeat does 
not show dramatic modal size increase in culture, we completely inactivated FAN1 by CRISPR/Cas9 editing in 
an HD iPS cell line with 73 CAGs. The result, as assessed from the calculated expansion index 19 of dividing 
iPSC clonal lines, was a gradual increase in the appearance of CAG repeats larger than the starting modal 
length over the course of continued culture (Fig. 4C; Fig. S12), indicating that FAN1 normally functions to 
stabilize the expanded CAG repeat.  
Effects of modifier haplotypes on FAN1 expression levels 
In the recent GWAS publication, we reported correlations between the modification signals from 15AM2 (not 
15AM1 or 15AM3), and FAN1 eQTL signals in the cortex subset of the GTEx Consortium data.10 We have not 
observed similar correlations for MTMR10 or TRPM1 eQTL signals (data not shown). To confirm in a larger 
data set that altered expression of FAN1 could explain some modifier effects, we performed eQTL analysis 
using the CommonMind Consortium (CMC) data. As shown in Fig. 5, genome-wide significant eQTL signals for 
FAN1 were generated by SNPs tagging the 15AM2 haplotype but not those tagging the 15AM1, 15AM3 or 
15AM5 modifier haplotypes. In agreement with these observations, co-localization analysis of HD modifier 
association data and CMC eQTL data showed posterior probabilities for the effects sharing the same causal 
variant of 97.0% for SNPs tagging 15AM2. In contrast, 15AM1-, 15AM3-, and 15AM5-tagging SNPs revealed 
posterior probabilities of 8.3%, 8.5%, and 9.8%, respectively, for the HD modifier and eQTL effects sharing the 
same causal variant (Fig 5C). Comparison of the directions of the eQTL and onset modification signals 
confirmed that the onset-delaying 15AM2 modifier effect is associated with a relative increase in the level of 
FAN1 mRNA expression.  
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Additional analyses for FAN1 did not reveal any compelling evidence supporting a role for splicing as a 
genetic modifier of HD (GTEX portal). Taken together, the haplotype/sequencing data and eQTL analyses 
support the suspected role of FAN1 as the gene responsible for the 4 independent modifier signals on chr15, 
with the causal variants on the 15AM1 and 15AM3 modifiers likely being the FAN1 missense changes, 
rs150393409 and rs151322829, respectively; the 15AM2 modifier acting through alteration of FAN1 mRNA 
levels. The mechanism by which the 15AM5 modifier acts is not clear and requires further investigation. 
Effect of modifier genotype on age-at-onset modification 
The individual SNP association analyses as performed in the GWA studies are based upon the assumption of 
additivity across major allele homozygotes, heterozygotes and minor allele homozygotes. Once the modifier 
haplotypes were defined, it became possible to use the tag SNPs to test whether the mechanisms underlying 
the modifier effects at this particular locus, which include both structural changes to FAN1 and differences in 
mRNA expression level in cortex, are indeed additive or, alternatively, show evidence of non-additive effects. 
Of the 9,058 GWA study subjects, 3,868 (42.7%) carried a haplotype other than 15AM1, 15AM2, 15AM3, or 
15AM5 (i.e, a non-modifier or “Other” haplotype based on the 4 top tag SNPs), most frequently as a 
heterozygote with one of the modifier haplotypes (Table 2, top section). We first determined the effect size 
attributable to one copy of 15AM1, 15AM2, 15AM3 or 15AM5 by 1) selecting HD GWA subjects with one 
chromosome bearing the minor allele of the corresponding haplotype tag SNP and one chromosome with only 
major alleles at all 4 tag SNPs (i.e., a non-modifier chromosome or “Other” in Table 2) and then 2) comparing 
their residual age-at-onset to individuals bearing only two non-modifier chromosomes, with the difference in the 
respective residuals constituting the effect attributable to the modifier haplotype.  
Having determined the effect size for a single copy of each modifier allele, we were then able to 
examine individuals carrying two modifier chromosomes. Under the additive model, for any given diplotype the 
expected residual age-at-onset can be predicted by simply adding the individual effect sizes of the haplotypes 
represented. Diplotypes that included 15AM2, which is reasonably frequent, showed no significant deviation 
(Student's t-test, p-value = 0.9175) from the additivity-based expectation (Table 2, middle section), indicating 
that each copy of 15AM2, which appears to act as an onset-delaying modifier through increased FAN1 
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expression in the cortex, has its effect independently of whether the other chromosome 15 bears another 
15AM2 copy, a copy of one of the onset-hastening modifiers, or a non-modifier version of the locus.   
All other combinations of modifier haplotypes (involving either homozygosity or compound 
heterozygosity for onset-hastening modifiers) are infrequent (Table 2, bottom section).  All showed a residual 
age-at-onset that is more negative than expected (i.e., even earlier onset than predicted by additivity of the 
effects), a difference that over the entire group is statistically significant (Student's t-test, p-value = 0.03162). 
The fact that absence of any non-modifier FAN1 in an individual (i.e., 2 onset hastening-haplotypes) produces 
a worse outcome than predicted from onset-hastening modifier heterozygotes indicates that the presence of a 
non-modifier FAN1 locus does act to mitigate to some degree the effect of the onset-hastening modifiers.  The 
sample size for this group is small and therefore additional samples will be needed to replicate this finding and 
to examine the behavior of the individual onset-hastening modifier haplotypes. 
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Discussion 
Our GWAS study of HD age-at-onset identified multiple modifier loci that remarkably, at or near the peak 
association signal, had the presence of a gene involved in DNA maintenance processes, suggesting that these 
genes are the sources of HD modification. At the 15q13.2-13.3 locus, the corresponding candidate gene was 
FAN1 (Fanconi-Associated Nuclease 1) which encodes a protein involved in repair of ICL-induced DNA breaks, 
by cleaving DNA at every third nucleotide from a cut end using its 5'-3' exonuclease activity.16 Further, while 
FAN1 does not participate in DNA double-strand break resection, it is required for efficient homologous 
recombination.22; 24 Consequently, we set out to establish whether FAN1 is indeed the modifier gene at this 
locus in order to guide strategies for therapeutic intervention and provide genetic guidance for clinical trial 
design. Taken together, our genetic and molecular data confirm that FAN1 is the source of the chr15 locus 
modifier effect in HD and strongly point to altered FAN1 DNA binding activity (15AM1, 15AM3) and expression 
level (15AM2) as sources of onset-hastening and onset-delaying modification, respectively. Interestingly, the 
p.Arg507His and p.Arg377Trp variants associated with the 15AM1 and 15AM3 HD modifier effects were
reported originally in early-onset breast cancer families, 25 but, despite a plausible argument for FAN1 function 
playing a role in tumorigenesis, these substitutions are not associated with increased risk of breast cancer in 
the general population. There is however evidence for a functional impact in vivo as the p.Arg507His 
substitution on 15AM1 has recently been associated in genetic studies with karyomegalic interstitial nephritis, a 
recessively inherited disease caused by loss of FAN1 function.26 Our genetic data also indicate that some as 
yet undetermined mechanism other than a protein-altering variant can also result in earlier than expected onset 
(15AM5). Finally, the previously named haplotype 15AM410  does not represent a single independent modifier 
effect, but rather combinations of the effects of the 15AM1, 15AM2, 15AM3, and 15AM5.  
The mirrored effects of reduced function (reduced DNA binding activity of 15AM1 and 15AM3) and 
increased expression (15AM2) of FAN1 on the timing of HD onset suggest that a process involving FAN1 could 
represent a therapeutic target for slowing HD pathogenesis. In addition to FAN1, several other genes 
associated with DNA maintenance processes, including MLH1, MSH3, PMS1, PMS2, and LIG1, map in the 
vicinity of HD modifier GWAS signals on other chromosomes. The modifying effects of such DNA maintenance 
genes could theoretically influence HD pathogenesis by modulating accumulated DNA damage across the 
genome. However, the fact that the timing of HD onset is determined by a property of the CAG repeat, rather 
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than by continuous polyglutamine toxicity, favors a model in which these genetic modifiers act on the CAG 
repeat to alter its rate of somatic expansion. A role for FAN1 in the process of CAG repeat expansion has been 
supported by recent studies of an HD exon 1 minigene in FAN1 knock-out osteosarcoma cells, where CAG 
repeats of 30 and 70 CAGs were stable while modal repeats of 97 and 118 showed an increase in size during 
40 days of culture.12 The osteosarcoma cell assay did not distinguish the effects of wild-type FAN1, 
p.Arg507His variant FAN1 or a nuclease-inactive variant of FAN1 when these were each introduced via
expression construct, suggesting that expression at endogenous levels or for a longer period of time might be 
required to assess a functional impact of the missense variant on expansion. Alternatively, FAN1’s participation 
in the mechanism of repeat instability may not be precisely same in dividing cells and in non-dividing post-
mitotic neurons.  For example, the minor allele at FAN1 rs3512 is associated with increased repeat expansion 
in the blood cells of HD subjects27 but, as part of the 15AM2 haplotype, is associated with delayed age at onset 
and a suspected decrease in CAG expansion in neurons.  Consequently, it remains unclear whether FAN1 
acts in neurons through its ICL-resolving role or through some other function in DNA maintenance processes.   
Although in our assays a difference in DNA binding for FAN1 containing either of the two missense 
variants was readily detectable in transfected cells, and LCLs with these mutations showed increased 
sensitivity to MMC, we focused our assessment of CAG expansion on the endogenous repeat in clonal HD 
patient-derived iPS cells from a subject with 73 CAGs. As monitored by our established expansion index 
measure,19 in iPS cells with intact FAN1 alleles, this starting repeat was relatively stable through the relatively 
short 6 month culture assay, as might be expected from the multi-year time-course of somatic expansion 
postulated to lead in vivo to clinical onset in HD subjects. In parallel isogenic lines with no FAN1 due to 
CRISPR/Cas9-mediated inactivation, we observed a slow, gradual increase in expansion index. A more 
exaggerated response has been seen in another human HD iPS cell line with a longer, inherently unstable 
repeat, where ongoing CAG expansion was increased by partial FAN1 shRNA knockdown.12 Taken together 
with the increased expression level associated with the 15AM2 modifier and its onset-delaying effect, these 
studies argue that wild-type FAN1 functions to suppress CAG repeat expansion, a conclusion that also 
supports the candidacy of FAN1 as a potential modifier of other CAG repeat disorders 28 and, as suggested in 
a recent report that Fan1 knock-out enhances somatic expansion of CGG repeats in a model of Fragile X 
disorders,11 implies a role for FAN1 more broadly in triplet repeat diseases. 
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A role for FAN1 in suppressing somatic CAG expansion, combined with the onset-delaying effect of the 
15AM2 modifier haplotype, suggest that increasing the expression of wild-type FAN1 could have therapeutic 
benefit in delaying the onset of HD. The additivity of the 15AM2 effect in the presence of either a second 
15AM2 allele or a 15AM1, 15AM3 or 15AM5 allele indicates that such a treatment could be widely applicable. 
Increased FAN1 expression could theoretically be achieved by upregulating an endogenous allele, but this 
would require that the subject expresses a wild-type coding sequence from at least one allele. It is also not 
certain whether this upregulation would have to be chromosome-specific, since we cannot assess from the 
population analysis any potential negative effect of upregulating the 15AM1, 15AM3 or 15AM5 chromosomes. 
An alternative strategy would be to introduce exogenous FAN1, which might be particularly effective for 
subjects with two onset-hastening modifiers. Even if FAN1 expression is not the mechanism chosen for 
therapeutic intervention, knowledge of the FAN1 diplotype in an HD subject can be of potential importance for 
designing clinical trials of other mechanisms of intervention. For any trial in which conversion from premanifest 
to manifest disease is used as a measure, incorporating FAN1 genotype and its onset-modifying effect could 
either guide selection of trial subjects or provide greater precision in calculating the effect of treatment. 
Similarly, FAN1 genotype may be useful in the premanifest phase of HD where it has been shown to influence 
measures such as putamen volume and symbol digits modalities test score.29 Whether FAN1 genotype also 
influences the rate of progression of individual measures in manifest disease subjects and could be used in 
early HD trials remains to be determined. Additionally, if the intervention being tested is aimed specifically at 
blocking the process of somatic CAG expansion, then FAN1 genotype and knowledge of any potential genetic 
interactions with other HD modifier genes that might interfere with or enhance the ability to reliably measure 
outcomes will also be crucial. 
HD is a devastating disorder without treatments effective in delaying onset or slowing the worsening of 
disease manifestations. We undertook the characterization of genetic modifiers that alter the course of the 
human disease as a potential route to effective mechanism-based treatments. The accumulated evidence 
supporting FAN1 as the HD modifier gene at the 15q13.2-13.3 locus reinforces the view that each of the DNA 
maintenance genes at or near modifier signals on chromosomes 2 (PMS1), 3 (MLH1), 5 (MSH3), 7 (PMS2) 
and 19 (LIG1) will prove to be the respective sources of HD modification through influences on somatic 
expansion of the CAG repeat. Similarly, these findings suggest that other GWA loci without known DNA 
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maintenance genes may point to genes that also participate in the CAG repeat expansion process even though 
they are not currently recognized as being involved in DNA repair (e.g., RRM2B on chromosome 8, CCDC82 
on chromosome 11). The success of this GWAS strategy as applied to the timing of HD onset dictates that this 
approach also be applied to other landmarks in the HD disease process and to the rate of worsening disease, 
particularly during the period of early manifest HD most applicable to clinical trials, in order to maximize the 
opportunity to identify therapeutic targets for effective treatments that alleviate the suffering of families with this 
devastating disease.  
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 Table 1. Reconstructed onset modifier haplotypes based on KGP data and supplemental capture sequencing data. 
(A) Since the causal variations responsible for onset modification signals must exist within the region of association, we constructed the consensus
haplotype for the chromosomal regions responsible for each of the 4 modifier effects. Panels of modifier haplotype-tagging SNPs (peak SNP + 
SNPs with R-square>0.8) were used to define the analysis regions and to identify modifier haplotypes in KGP data for subsequent analysis focusing 
on functional variants. For example, the 15AM1 consensus haplotype was constructed based on 12 KGP chromosomes identified by 3 15AM1-
tagging SNPs. In the region defined by 15AM1-tagging SNPs (chr15: 31202961 - 31300677), 2,836 SNPs are described in the KGP data, and 1,703 
of them were tested in our association analysis. Among tested variants, the 15AM1 consensus haplotype carries alternative alleles at 120 sites; 2 of 
those are annotated as protein-altering variations (rs150393409 and rs3784588). Of 1,133 not-tested variants, the 15AM1 consensus haplotype 
carries alternative alleles at 1 site (not protein-altering).  
(B) Independently, representative HD samples carrying modifier haplotype-tagging SNPs were sequenced by a targeted capture sequencing
method. DNA samples were heterozygous for 15AM1 (18 samples), 15AM3 (3 samples) or 15AM5 (3 samples), or were homozygous for 15AM2 (8 
samples). Allele frequencies observed in the sequence data across the modifier haplotypes were compared to the expected allele frequency of the 
causal variation (50% for heterozygous subjects, 100% for homozygous subjects) focusing on protein-altering variants. Analysis focusing on other 
exon SNPs that were not annotated in KGP data did not reveal any variants with expected allele frequencies.  
a Among 46 15AM2-tagging SNPs, 36 SNPs passed QC for capture sequencing analysis.  
29 
KGP data: Haplotype-based analysis 
Modifier haplotype 15AM1 15AM2 15AM3 15AM5 
Number of tagging SNPs with R2 > 0.8 3 46 3 2 
Modifier haplotype boundary 
(size) 
31202961 - 31300677 
(97.7 KB) 
31184803 - 31285422 
(100.6 KB) 
31165091 - 31221358 
(56.2 KB) 
31204637 - 31282611 
(77.9 KB) 
Number of chromosomes carrying the haplotype 12 400 7 37 
Variation sites in KGP in the region 2836 2965 1669 2292 
Tested for HD onset modification 1703 1756 936 1379 
Site with reference allele 1583 1652 899 1354 
Site with alternative allele 120 104 37 25 
Protein-altering variants 
2 
(rs150393409, 
rs3784588) 
0 1 (rs151322829) 
1 
(rs6493352) 
Not tested for HD onset modification 1133 1209 733 913 
Sites with reference allele 1132 1203 727 912 
Sites with alternative allele 1 6 6 1 
Protein-altering variants 0 0 0 0 
Capture sequencing data 
Modifier haplotype 15AM1 15AM2 15AM3 15AM5 
Modifier haplotype boundary 
(size) 
31202961 - 31300677 
(97.7 KB) 
31184803 - 31285422 
(100.6KB) 
31165091 - 31221358 
(56.2 KB) 
31204637 - 31282611 
(77.9 KB) 
Number of QC-passed tagging SNPs 3 36 a 3 2 
Samples (chromosomes) carrying the haplotype 18 (18) 8 (16) 3 (3) 3 (3) 
Expected frequency of casual variant (%) 50 100 50 50 
Protein-altering SNP with expected frequency rs150393409 0 rs151322829 rs6493352 
Other exon SNP with expected frequency 0 0 0 0 
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Table 2. Test whether combinations of two modifier haplotypes are additive or synergistic.  
To estimate the effect size of each modifier (top section), we identified HD subjects carrying only one copy of 
either 15AM1, 15AM2, 15AM3, or 15AM5, and compared them with HD subjects without any of these modifier 
haplotypes ('Other' group as the baseline). For example, the effect size of 15AM1 was calculated by 
subtracting the observed residual age-at-onset of the "Other" group from that of HD subjects carrying one copy 
of the 15AM1 modifier haplotype. N represents the number of HD subjects. 
We then determined whether the onset-delaying effect of a single 15AM2 chromosome is influenced by 
the presence of a second modifier haplotype (middle section). Expected residual age-at-onset of each group 
was based on the effect sizes estimated in the top section. 
Finally, a small number of HD subjects carry two copies of infrequent onset-hastening modifier 
haplotypes (i.e., 15AM1, 15AM3, and 15AM5; bottom section). To determine whether two onset-hastening 
modifier haplotypes generate non-additive effects, we compared the residual age-at-onset based upon addition 
of effect sizes from the top section to observed residuals. Student's t-tests were performed to determine 
whether observed residuals and expected residuals were significantly different.  
Subjects with one modifier haplotype and effect size estimation 
1st Chr 2nd Chr N Observed residual (years) Effect size (years) 
Other Other 3868 -0.55 Baseline 
15AM1 Other 164 -5.02 15AM1 : -4.47 
15AM2 Other 3621 0.64 15AM2 : 1.19 
15AM3 Other 89 -3.90 15AM3 : -3.35 
15AM5 Other 227 -2.72 15AM5 : -2.17 
Effects of selected modifier haplotypes in the presence of 15AM2 
1st Chr 2nd Chr N Observed residual (years) Expected residual (years) 
15AM1 15AM2 85 -4.21 -3.83
15AM2 15AM2 851 1.81 1.83 
15AM3 15AM2 30 -2.92 -2.71
15AM5 15AM2 105 -1.69 -1.53
 Student's t-test, p-value = 0.9175 
Subjects with two onset-hastening modifier haplotypes 
1st Chr 2nd Chr N Observed residual (years) Expected residual (years) 
15AM1 15AM1 1 -21.76 -9.49
15AM1 15AM3 2 -13.40 -8.37
15AM1 15AM5 6 -9.38 -7.19
15AM3 15AM3 2 -10.83 -7.25
15AM3 15AM5 1 -15.57 -6.07
15AM5 15AM5 6 -8.13 -4.89
 Student's t-test, p-value = 0.03162 
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Figure Legend 
Figure 1. Dense SGV marker association with residual age-at-onset at the chromosome 15 HD modifier 
locus.  
All SGVs (dark grey, QC-passed; light grey, QC-failed), merged from two sets of imputed genotype data, were 
evaluated for the levels of association with residual age-at-onset. For each test variant, the residual age-at-
onset as a continuous phenotype was modeled as a function of minor allele count (additive model), sex, 
ancestry characteristics, and study group in a fixed effect model. Y-axis and X-axis represent the levels of 
significance of association and genomic coordinate (GRCh37/hg19), respectively. Up-ward and down-ward 
triangles represent SNPs whose minor alleles are associated with delayed and hastened age-at-onset, 
respectively. Filled blue and red triangles represent protein-altering variants, with the latter predicted to be 
deleterious / damaging. Traces in blue and red represent the frequencies of duplication and deletion from the 
CNV analysis of the study samples (secondary Y-axis). All RefSeq transcripts for a given gene were combined 
to show locations of exons (vertical bars) and introns; gene symbols in red and blue represent genes on plus 
and minus strands, respectively. In the region of genome-wide significant signal, only FAN1, MTMR10 and 
TRPM1 are protein-coding genes. Two genome-wide significant and deleterious missense SNPs are indicated 
by black arrows.  
Figure 2. Refinement of top tag SNPs and identification of an additional onset-hastening modifier effect. 
(A) To discover additional independent modifier haplotypes, we excluded samples carrying 15AM1 or 15AM3
haplotypes, and performed association analysis. After drop-out of these infrequent onset-hastening haplotypes, 
the peak SNP tagging the common onset-delaying 15AM2 haplotype was rs8034856 (dark green circle) rather 
than the original rs35811129 (light green circle). Interestingly, a relatively infrequent SNP remained significant, 
suggesting the existence of an independent modifier haplotype tagged by rs79213781 (cyan circle).  
(B) To confirm that the modifier effect tagged by rs79213781 (cyan circle) is independent, the new tag SNP for
15AM2 (rs8034856) was used for conditional analysis of the sample set excluding carriers of 15AM1 or 15AM3. 
Dotted lines indicate genome-wide significant association.  
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Figure 3. FAN1 missense variants on 15AM1 and 15AM3 modifier haplotypes reduce DNA binding. 
(A) Through sequence analysis, we fully re-constructed FAN1 modifier haplotypes at the levels of nucleotide
and amino acid. Subsequently, LCLs from representative HD patients were used for cDNA cloning to generate 
full length mammalian expression constructs for the modifier haplotypes 15AM1 and 15AM2. Since 1) cell lines 
carrying the modifier haplotype 15AM3 were not readily available due to low allele frequency, and 2) the 
modifier haplotype 15AM3 differs from 15AM2 at one nucleotide, site directed mutagenesis was performed to 
generate the expression vector for 15AM3. The FAN1 sequence of 15AM5 is identical to that of 15AM2, and 
therefore the effects of 15AM5 modifier FAN1 can be tested by using the 15AM2 modifier FAN1 construct 
(second diagram). Each construct has a FLAG tag at the N-terminus for biochemical assays. Subsequent 
sequencing analysis of expression constructs confirmed the DNA sequence reconstructed by KGP data 
analysis and capture sequencing. Black triangles indicate deleterious/damaging missense variations. Domains 
are shown: UBZ, SAP, TPR, and NUC represent ubiquitin binding Zinc finger, SAF-AIB, Acinus and PIAS 
(DNA binding domain), tetratricopeptide repeat, and virus type replication repair nuclease, respectively. 
Diagrams of haplotypes were focused on FAN1 because modifier haplotype-specific variations do not alter 
protein sequence or are not associated with expression levels of other nearby genes (e.g., MTMR10, TRPM1).  
(B) DNA binding activities of the 3 different FAN1 proteins were determined by in vitro assays using 3' flap
comprising a set of 3 oligos. FLAG-tagged FAN1 protein nuclear extract and biotinylated oligos were incubated, 
and the protein-oligo complex was pulled down by streptavidin. The amount of FAN1 was quantified by 
immunoblot analysis using FAN1 antibody, and data were normalized by the amount of FAN1 in the inputs. 
DNA binding activity on the Y-axis represents densitometry reading of pull-down divided by that of input for 
each group (A.U., arbitrary unit). Five independent experiments were summarized (5 technical 
replicates/group).  
(C) Similarly, DNA binding activity of FAN1 was determined using oligos of 10 CAG loop-out (potentially
forming 5 CAG long hairpin/loop structure). Experiments were repeated three times (3 technical 
replicates/group). Error bars represent the standard errors. *, p-value < 0.05; **, p-value < 0.01. 
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Figure 4. Reduced rescue from MMC-mediated toxicity by 15AM1 and 15AM3. 
(A) FAN1 knock-out HEK293T cells were used to determine the levels of rescue afforded by over-expression of
different FAN1 haplotypes. FAN1 knock-out HEK293T cells were treated with either vehicle (-) or MMC (+; 10 
µM for 24 hrs), and then viability assays were performed to determine the levels of rescue from the MMC-
induced cytotoxicity. Viability in the absence of MMC treatment was considered as 100% (i.e., control) for each 
experimental group. Error bars represent standard errors (12 technical replicates/condition from 3 independent 
experiments). NS, not significant 
(B) LCLs derived from HD subjects carrying either 15AM1 (red; 5 lines, all heterozygous for 15AM1) or 15AM2
modifier FAN1 (green; 3 and 2 lines heterozygous and homozygous for the 15AM2, respectively) were treated 
with various concentrations of MMC to determine viability by Cell Titer-Glo assay. Vehicle treated cells were 
used as controls. We hypothesized that the expression levels of FAN1 in cells were similar due to the lack of a 
significant FAN1 eQTL in LCL (Fig. S11). LCLs with 15AM3 were not available due to the low frequency of the 
haplotype, and therefore were not tested. Error bars represent standard errors (5 biological repilcates/group, 
24 technical replicates/condition for each biological replicate from 4 independent experiments). **, p-value < 
0.01; ***, p-value < 0.001; ****, p-value < 0.0001 by Student's t-test. 
(C) FAN1 was knocked out in iPSC derived from a HD subject (carrying 72/15 CAGs and two copies of 15AM2
modifier haplotype) by CRISPR/Cas9. Subsequently, 2 clonal lines for FAN1 knock-out (KO; starting modal 
CAGs 75 and 72, respectively) and 2 control lines (empty vector treated; starting modal CAGs 74 and 73, 
respectively) were established. These cells were maintained in standard iPSC culture conditions, and DNA 
samples were collected longitudinally and analyzed by PCR sizing to calculate expansion index. Thus, these 
data represent the levels of CAG repeat instability in proliferating iPSC, not differentiated neurons. Each data 
point represent a single measurement. Fluctuations seen in KO clones (#1 at 4 months and #2 at 5 months) 
might be due to the possibility that some of expanded alleles were filtered out by 10% peak height threshold in 
our expansion index quantification procedure because of low PCR amplification efficiencies in corresponding 
samples.  
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Figure 5. Co-localization of 15AM2 modification signals and FAN1 eQTL signals. 
(A) eQTL analysis was performed using RNAseq and genotype data sets from the CMC, focusing on FAN1.
Expression levels of FAN1 were modeled as a function of a test SNP and covariates in a fixed effect model. Y-
axis and X-axis represents significance in eQTL analysis (i.e., -log10(p-value)) and genomic location (GRCh 
37/hg19), respectively. Haplotype-tagging SNPs are indicated by colored symbols (red, 15AM1, green, 15AM2; 
purple, 15AM3; cyan, 15AM5). 
(B) Signals (i.e., -log10(p-value)) in HD modifier GWA data (X-axis) and CMC FAN1 eQTL data (Y-axis) were
compared for shared SNPs between two data sets. 
(C) Co-localization analysis was performed using modifier association data and FAN1 eQTL data of haplotype-
tagging SNPs. Percent posterior probability was calculated for 1) causal variant for HD onset modification only, 
2) causal variant for FAN1 eQTL only, and 3) common causal variant for both HD onset modification and FAN1
eQTL using haplotype-tagging SNPs. 
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Co-localization analysis: HD modifier association analysis data and CMC eQTL data
Posterior probability (%) 15AM1-tagging SNPs 15AM2-tagging SNPs 15AM3-tagging SNPs 15AM5-tagging SNPs
1. Causal variant for HD modifier trait only 92 2.4E-9 89 90
2. Causal variant for CMC eQTL trait only 5.8E-21 5.1E-20 4.6E-4 3.6E-6
3. One common causal variant 8.3 97 8.5 9.8
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